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Abstract
Polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) are myeloproliferative
disorders (MPD) that arise from the clonal proliferation of a pluripotent hematopoietic progenitor, leading to the over-
production of one or more myeloid lineages. Recently, a specific mutation in the JAK2 gene, which encodes a tyro-
sine kinase, has been shown to be associated with the myeloproliferative phenotype observed in PV, ET and IMF. In
this study of Brazilian patients, the JAK2 V617F mutation [c.1887G > T) was detected in four out of 49 patients with
PV (96%), 14 out of 25 patients with IMF (56%), and in eight out of 29 patients with ET, which is in accordance with
previous screenings of this mutation in other populations.
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Polycythemia vera (PV), essential thrombocythemia
(ET), idiopathic myelofibrosis (IMF) and chronic mye-
locytic leukemia (CML) are myeloproliferative disorders
(MPD) that have been shown to arise clonally from a
pluripotent hematopoietic stem cell (Fialkow et al., 1967;
Adamson et al., 1976; Jacobson et al., 1978; Fialkow et al.,
1981). Important manifestations of these disorders are bone
marrow hypercellularity and pan-myeloid myeloprolife-
ration, leading to overproduction of one or more hemato-
poietic lineages (Spivak et al., 2003). In addition, constant
hallmarks of MPD bone marrow cells are their hypersensi-
tivity to several cytokines (Prchal and Axelrad, 1974; Dai et
al., 1992; Correa et al., 1994; Dai et al., 1994) and their abil-
ity to generate EPO-independent erythroid colonies in vitro
(Prchal and Axelrad, 1974), commonly referred to as endog-
enous erythroid colonies (EECs). Recently, gene JAK2,
which encodes a tyrosine kinase required for effective sig-
naling in response to several cytokines (Parganas et al.
1998), was found mutated in these conditions. A somatic
mutation, c.1887G > T (p.Val617Phe), ref. sequence
NM_004972, commonly known as JAK2 V617F, has been
described in the majority of patients with PV and in a subset
of patients with ET and IMF (Baxter et al., 2005; James et
al., 2005; Kralovics et al., 2005; Levine et al., 2005; Zhao et
al., 2005). It is noteworthy that among the growth factors to
which MPD hematopoeitic progenitors are hypersensitive,
EPO, SCF, GM-CSF, IL3, TPO and IGF-1 use JAK2 for sig-
naling (Kaushansky, 2005). It has been demonstrated that the
valine-to-phenylalanine substitution at amino acid position
617 leads to constitutive tyrosine phosphorylation activity
and promotes cytokine hypersensitivity (James et al., 2005;
Kralovics et al., 2005; Levine et al., 2005; Zhao et al., 2005).
Moreover, EEC colonies cloned from PV patients were all
shown to carry the mutation (Baxter et al., 2005), and le-
thally-irradiated mice transplanted with JAK2 V617F-
expressing bone marrow developed substantial erythro-
cytosis (James et al. , 2005). These observations indicate that
this mutation contributes to the myeloproliferative pheno-
type, a finding with direct implications in the establishment
of diagnosis protocols and the patient management (Camp-
bell and Green, 2005). Establishing the prevalence of this
mutation in patients with PV, ET and IMF is of practical im-
portance. This prompted us to carry out what is, to our
knowledge, the first screening of the JAK2 V617F mutation
in Brazilian patients with PV, ET and IMF.
Peripheral blood samples were obtained from 49 pa-
tients with PV, 25 patients with IMF, and 29 patients with
ET, seen at the Haematology and Haemotherapy Centre
(UNICAMP, Brazil), from July through December, 2005.
The diagnoses of PV, IMF and ET were made according to
the World Health Organization (WHO) criteria, based on
peripheral blood counts and bone marrow histology. Pe-
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ripheral blood samples from eight healthy volunteers were
used as controls, since no healthy individuals have been
shown to harbor the JAK2 V617F mutation (Baxter et al.,
2005; James et al., 2005; Kralovics et al., 2005; Levine et
al., 2005; Zhao et al., 2005). The study protocol was ap-
proved by the local ethics committee, and informed consent
was obtained from all patients. Genomic DNA was ex-
tracted using the GFX Genomic Blood DNA Purification
Kit (Amersham-Life Science). The presence of the JAK2
V617F mutation was assessed as previously described
(Baxter et al., 2005). JAK2 amplicons were obtained using
primers JAK2 forward (5’-GGGTTTCCTCAGAACGTT
GA-3’) and JAK2 reverse (5’-TCATTGCTTTCCTTTTT
CACAA-3’). PCR amplifications were performed in 50 μL
reaction mixes containing 50-100 ng of genomic DNA,
0.2 mM dNTP’s, 2 mM MgCl2, 0.2 pmol of each primer,
1X PCR buffer, and 1U Taq DNA polymerase. The cycling
parameters were as follows: 96 °C for 2 min followed by
45 cycles at 96 °C for 30 s, 57 °C for 30 s, and 72 °C for
1 min. The 460 bp PCR product (Figure 1A) was submitted
to Bsa XI (New England BioLabs inc.) digestion, for 16 h at
37 °C, and analyzed on a 2% agarose gel. The JAK2
wild-type allele yields 241 bp, 189 bp and 30 bp Bsa XI
fragments, while the JAK2 V617F allele remains undi-
gested, since the mutation causes loss of the enzyme site.
The Bsa XI digestion pattern in JAK2 V617F-negative pa-
tients and healthy controls is shown in Figure 1B, lanes 1
and 4. Patients who are positive for the mutation have both
the undigested 460 bp fragment, corresponding to the JAK2
V617F allele, and the Bsa XI fragments of the JAK2
wild-type allele (Figure 1B, lanes 2 and 3). The intensity of
the digested fragments visualized on the agarose gel varies
from patient to patient, due to differences in the homozy-
gous or heterozygous status of the mutation and in the pro-
portion of clonal cells in the total population. This appears
to be a time- and cost-effective methodology for the detec-
tion of the JAK2 V617F mutation.
Among the 49 patients with PV studied, the JAK2
V617F mutation was detected in 47 (96%). Among the pa-
tients with IMF, 14 out of 25 (56%) had the mutation, while
eight (28%) of the 29 ET patients were positive. These fre-
quencies are in agreement with those previously reported
(Table 1).
There are already studies in the literature on the con-
tribution of the JAK2 mutation to clinical status and disease
severity. A prospective study suggests that two ET sub-
types can be defined according to the JAK2 genotype, and
that ET patients carrying the JAK2 V617F mutation have
phenotypic similarities with PV patients (Campbell et al.,
2005). A multicentric study of IMF patients demonstrated
that there is no correlation between many of the clinical fea-
tures and the presence of the JAK2 V617F mutation, but, in-
terestingly, JAK2 V617F-positive patients had a decreased
survival (Campbell et al., 2006). It has been shown that,
while most of the clinical characteristics of PV did not dif-
fer between JAK2 V617F homozygous and heterozygous
patients, the former had higher hemoglobin levels at the
time of diagnosis, increased incidence of pruritus, higher
rates of fibrotic transformation, and higher PRV-1 tran-
script levels in granulocytes (Tefferi et al., 2006).
The discovery of this mutation has direct implications
in the establishment of diagnosis protocols and in the man-
agement of patients (Campbell and Green, 2005), and has a
great potential for the classification of MPDs and for the
development of target therapy (Vainchenker and
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Figure 1 - JAK2 V617F screening by PCR and Bsa XI digestion. Lanes
1-3: Patients with (1) essential thrombocythemia, ET; (2) polycythemia
vera, PV; (3) idiopathic myelofibrosis, IMF. Lane 4: Control individual.
(A) 460 bp undigested PCR product; lane M, λ-Hind III fragments (New
England BioLabs Inc.); (B) Bsa XI digestion of the 460 bp PCR product
yields 241 bp, 189 bp and 30 bp fragments from the wild-type allele; the
fragment corresponding to the JAK2 V617F mutation remains undigested:
normal alleles in a patient with ET (1); a normal and a mutated allele in pa-
tients with PV (2) and IMF (3); normal alleles in a control individual (4).
Lane M, 100 bp molecular weight ladder (New England BioLabs Inc.).
Table 1 - Frequencies of the JAK2 V617F mutation in Brazilian patients and in patients from the literature presenting with polycythemia vera, idiopathic
myelofibrosis and essential thrombocythemia.










Polycythemia vera 47/49 (96%) 71/73 (97%) 40/45 (89%) 83/128 (65%) 121/164 (74%) 20/24 (84%)
Idiopathic myelofibrosis 14/25 (56%) 8/16 (50%) 3/7 (43%) 13/23 (57%) 16/46 (35%) -
Essential thrombocythemia 8/29 (28%) 29/51 (57%) 9/21 (43%) 21/93 (23%) 37/115 (33%) -
Constantinescu, 2005). JAK2 genotyping of patients with
PV, IMF and ET is likely to become a clinically useful as-
say, and sensitive, effective techniques for the routine de-
tection of JAK2 V617F are being developed and tested
(James et al., 2006; McClure et al., 2006). Among the ques-
tions to be addressed in the investigation of the molecular
pathogenesis of MPDs is how a single mutation can give
rise to three phenotypically different diseases.
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